CN116444485B - Nonmetallic catalysis and column-free chromatographic synthesis method for pyridyl substituted asymmetric urea - Google Patents
Nonmetallic catalysis and column-free chromatographic synthesis method for pyridyl substituted asymmetric urea Download PDFInfo
- Publication number
- CN116444485B CN116444485B CN202310325909.3A CN202310325909A CN116444485B CN 116444485 B CN116444485 B CN 116444485B CN 202310325909 A CN202310325909 A CN 202310325909A CN 116444485 B CN116444485 B CN 116444485B
- Authority
- CN
- China
- Prior art keywords
- urea
- reaction
- amine
- pyridine
- secondary amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
【技术领域】【Technical field】
本发明属于化合物合成技术领域,具体涉及吡啶基取代不对称脲的非金属催化、免柱层析合成方法。The invention belongs to the technical field of compound synthesis, and specifically relates to a non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric ureas.
【背景技术】【Background technique】
N-吡啶基取代脲作为重要的杂环片段,为医药、化学、生物、材料等领域常见骨架。其中邻位吡啶基取代型,具有优良的抗肿瘤、抗糖尿病、神经保护、抑菌、缓解NASH(非酒精性脂肪肝炎)活性,应用广泛。As an important heterocyclic fragment, N-pyridyl-substituted urea is a common skeleton in the fields of medicine, chemistry, biology, materials and other fields. Among them, the ortho-pyridyl substituted type has excellent anti-tumor, anti-diabetic, neuroprotective, antibacterial, and NASH (non-alcoholic steatohepatitis) activities, and is widely used.
化合物1为GSK3/CDK5双重抑制剂,抗肺部细胞、结肠细胞增殖(Eur.J.Med.Chem.,2015,101,274–287)。Compound 1 is a dual inhibitor of GSK3/CDK5 and resists the proliferation of lung cells and colon cells (Eur. J. Med. Chem., 2015, 101, 274-287).
化合物2是高效的ERK选择性抑制剂,在BRAFV600E异种移植模型中显示肿瘤退缩效果(J.Med.Chem.,2016,59,6501–6511)。Compound 2 is a highly efficient selective inhibitor of ERK and shows tumor regression effect in the BRAFV600E xenograft model (J. Med. Chem., 2016, 59, 6501–6511).
化合物3,Golvatinib(E7050)是c-Met和VEGFR-2双重抑制剂,通过多靶点策略抗肿瘤血管生成,用于头颈部癌症治疗(Cancer Sci.,2015,106,201–207),还可以作为甲型肝炎病毒感染药物开发的先导物(PLOS Biol.,2019,17,e3000229)。Compound 3, Golvatinib (E7050), is a dual inhibitor of c-Met and VEGFR-2. It anti-tumor angiogenesis through a multi-target strategy and is used for the treatment of head and neck cancer (Cancer Sci., 2015, 106, 201–207). It can also be used as a lead for the development of drugs for hepatitis A virus infection (PLOS Biol., 2019, 17, e3000229).
化合物4,Roblitinib在2014年被FDA批准为首个进入临床的高选择性FGFR4抑制剂(J.Med.Chem.,2020,63,12542–12573)。Compound 4, Roblitinib, was approved by the FDA in 2014 as the first highly selective FGFR4 inhibitor to enter clinical practice (J. Med. Chem., 2020, 63, 12542–12573).
进一步优化结构的化合物5,作为有潜力的先导物,展现优越的激酶组选择性,药物代谢动力学特性更佳(J.Med.Chem.,2022,65,3249–3265)。Compound 5, whose structure was further optimized, serves as a potential lead, exhibiting superior kinome selectivity and better pharmacokinetic properties (J. Med. Chem., 2022, 65, 3249–3265).
化合物6是一个新颖的葡萄糖激酶活化剂,用于2型糖尿病的治疗(J.Med.Chem.,2014,57,8180–8186)。Compound 6 is a novel glucokinase activator for the treatment of type 2 diabetes (J. Med. Chem., 2014, 57, 8180-8186).
化合物7,GNF2133作为一种高效、选择性好、可口服的DYRK1A抑制剂,能改善I型糖尿病的相关症状(J.Med.Chem.,2020,63,2958–2973)。Compound 7, GNF2133, as a highly efficient, selective, orally available DYRK1A inhibitor, can improve symptoms related to type I diabetes (J. Med. Chem., 2020, 63, 2958-2973).
化合物1-10:Compounds 1-10:
在神经退行性疾病的治疗中,尤其针对阿尔茨海默病的调节,化合物8对人重组乙酰胆碱酯酶(hAChE)、糖原合成酶激酶-3α/β都具有显著的抑制作用,是潜在的多靶点定向配体(Eur.J.Med.Chem.,2019,168,58–77)。In the treatment of neurodegenerative diseases, especially for the regulation of Alzheimer's disease, compound 8 has a significant inhibitory effect on human recombinant acetylcholinesterase (hAChE) and glycogen synthase kinase-3α/β, and is a potential Multi-target targeting ligands (Eur. J. Med. Chem., 2019, 168, 58–77).
在抗炎领域,化合物9安全性好,对革兰氏阳性菌和呼吸道感染病原体,通过口服或者静脉滴注都有阻抑效果。遏制MAP3K激酶ASK1是治疗非酒精性肝病,包括脂肪性肝炎和多发性硬化的一种有吸引力的策略(J.Med.Chem.,2017,60,3755–3775)。In the field of anti-inflammatory, compound 9 has good safety and has inhibitory effect on Gram-positive bacteria and respiratory infection pathogens through oral administration or intravenous infusion. Inhibiting the MAP3K kinase ASK1 is an attractive strategy for treating non-alcoholic liver diseases, including steatohepatitis and multiple sclerosis (J. Med. Chem., 2017, 60, 3755–3775).
化合物10是有效的选择性小分子抑制剂,表现出更强的凋亡诱导,更优的G1细胞周期阻滞活性,更低的细胞IC50值,在HepG2癌症细胞系中的生长阻遏作用优于GS4997(Eur.J.Med.Chem.,2020,195,112277)。Compound 10 is an effective and selective small molecule inhibitor, showing stronger apoptosis induction, better G1 cell cycle arresting activity, lower cell IC 50 value, and excellent growth inhibition effect in HepG2 cancer cell line. In GS4997 (Eur. J. Med. Chem., 2020, 195, 112277).
因为自身特殊的氢键作用模式,吡啶脲片段也常用于多种功能复合材料。吡啶脲修饰的反式四氟偶氮苯,具有嵌入互补三重氢键单元,可通过光调控,发生反式-顺式光异构,引起分子结构的剧烈变化。线性反式状态的细微立体成因元素使其选择性折叠成顺式,从而产生手性光学特性增强的球状结构(Angew.Chemie Int.Ed.,2017,56,3349–3353)。2-吡啶基脲改性的二氧化硅作为固定相,显示出混合模式的中等弱阴离子交换能力和pH依赖性表面电荷反转(J.Chromatogr.A,2018,1560,45–54)。依据“钥匙+锁”结合目标客体的超分子化学原理与概念,为了在金属-有机框架材料(MOF)吸附流程中增强其选择性,可通过引入具有多个氢键基序的2-吡啶基脲实现,不仅能应用于MOF,而且适用于其他多种介孔材料,可以针对性地识别更大和复杂的分子,进而用于特定分离、传感器和药物递送(J.Mater.Chem.A,2019,7,10379–10388)。含2-吡啶脲单元的低聚物,吡啶氮原子和脲的NH形成分子内氢键,末端羰基和脲的NH产生分子间氢键。由于氢键的协同作用,能折叠并表现出强大的自组装行为,生成一个扭曲的平面,脲片段的羰基朝外,而NH倾向于内,此重要特征有利于NH吸引富电子物质。三聚体自行组装成螺旋纳米管并能高效地输送氯离子。利用此新颖有效策略构建自组装仿生体,可制备富电子物质传输材料(Angew.Chemie Int.Ed.,2021,60,10833–10841)。Because of its special hydrogen bonding mode, pyridine urea fragments are also commonly used in a variety of functional composite materials. Pyridyl urea-modified trans-tetrafluoroazobenzene has embedded complementary triple hydrogen bonding units, which can be regulated by light to undergo trans-cis photoisomerization, causing drastic changes in the molecular structure. Subtle stereogenic elements in the linear trans state allow it to selectively fold into the cis form, resulting in globular structures with enhanced chiral optical properties (Angew. Chemie Int. Ed., 2017, 56, 3349–3353). 2-Pyridylurea-modified silica was used as a stationary phase, showing a mixed-mode moderately weak anion exchange capability and pH-dependent surface charge reversal (J. Chromatogr. A, 2018, 1560, 45–54). According to the supramolecular chemistry principle and concept of "key + lock" combining target objects, in order to enhance the selectivity of metal-organic framework materials (MOF) in the adsorption process, 2-pyridyl groups with multiple hydrogen bonding motifs can be introduced Urea is realized, which can be applied not only to MOF, but also to a variety of other mesoporous materials, which can target the recognition of larger and complex molecules and then be used for specific separation, sensors and drug delivery (J.Mater.Chem.A, 2019 , 7, 10379–10388). In oligomers containing 2-pyridyl urea units, the pyridine nitrogen atom and the NH of urea form intramolecular hydrogen bonds, and the terminal carbonyl group and the NH of urea form intermolecular hydrogen bonds. Due to the synergistic effect of hydrogen bonds, it can fold and show strong self-assembly behavior, forming a twisted plane. The carbonyl group of the urea segment faces outwards, while NH tends to inward. This important feature is conducive to NH attracting electron-rich substances. The trimers self-assemble into spiral nanotubes and transport chloride ions efficiently. Using this novel and effective strategy to construct self-assembled biomimetic bodies, electron-rich material transport materials can be prepared (Angew. Chemie Int. Ed., 2021, 60, 10833–10841).
现有经典合成方案汇总:Summary of existing classic synthesis schemes:
在上述诸多应用中,吡啶脲及其衍生物的合成主要通过传统方法,包括异氰酸酯法、叠氮法、芳基卤化物的交叉偶联法、光气(或基于光气的替代品)法等:In many of the above applications, the synthesis of pyridyl urea and its derivatives is mainly through traditional methods, including isocyanate method, azide method, cross-coupling method of aryl halides, phosgene (or phosgene-based substitutes) method, etc. :
(1)异氰酸酯法:采用异氰酸酯与吡啶胺反应可以实现非对称脲的合成,但异氰酸酯活性非常高,本身难于制备和储存,通常需要较苛刻的条件,如严格的无水、无氧、氮气氛围保护,技术要求高,流程复杂,降低可操作性。(1) Isocyanate method: The synthesis of asymmetric urea can be achieved by the reaction of isocyanate and pyridine amine, but isocyanate is very reactive and difficult to prepare and store. It usually requires harsh conditions, such as strict anhydrous, oxygen-free, and nitrogen atmosphere. Protection, high technical requirements, complex processes, and reduced operability.
(2)叠氮法:酰基叠氮化合物经过Curtius重排,原位生成活泼的异氰酸酯中间体,再继续与胺反应可以制备非对称脲。其合成工艺较繁琐,主要由于无机/有机叠氮自身就存在危险、易爆的隐患。合成过程中安全性和可靠性都缺乏,此方法并不适用于大规模工业化生产。(2) Azide method: The acyl azide compound undergoes Curtius rearrangement to generate an active isocyanate intermediate in situ, and then continues to react with amine to prepare asymmetric urea. The synthesis process is complicated, mainly because inorganic/organic azide itself has dangerous and explosive risks. The synthesis process lacks safety and reliability, and this method is not suitable for large-scale industrial production.
(3)芳基卤化物的交叉偶联法:以Buchwald反应为主导的钯催化芳基卤化物交叉偶联,使用有毒且昂贵的重金属试剂,近年来,尽管全球许多研究组不断进行改进,为提高配合物催化效率,一般都需要有机膦配体的辅助,常规化反应条件严谨、苛刻。(3) Cross-coupling method of aryl halides: Palladium-catalyzed cross-coupling of aryl halides, dominated by the Buchwald reaction, uses toxic and expensive heavy metal reagents. In recent years, although many research groups around the world have continued to improve it, Improving the catalytic efficiency of complexes generally requires the assistance of organophosphine ligands, and the conventional reaction conditions are rigorous and harsh.
(4)光气(或基于光气的替代品)法:采用光气和胺缩合是合成有机脲的传统方法,在工业上也已经得以应用。由于原料光气是剧毒品,产生具有强腐蚀性和污染性的含卤废物,极易造成设备报废和严重的环境污染。此外,该方法不易制备非对称脲。光气的规模化利用有明显的缺点,科研工作者一直努力寻找其替代品,如光气聚合物、羰基二咪唑、氯甲酸苯酯等。但是反应总体收率通常较低,且产生大量废弃物。同时,这些化合物本身大多源自光气合成,综合考量,采用光气为原料或基于光气的替代品来制备非对称脲存在较大的局限性。(4) Phosgene (or phosgene-based substitute) method: The condensation of phosgene and amine is a traditional method for synthesizing organic ureas, and it has also been applied in industry. Since the raw material phosgene is a highly toxic substance, it produces highly corrosive and polluting halogen-containing waste, which can easily cause equipment scrapping and serious environmental pollution. In addition, this method is not easy to prepare asymmetric urea. The large-scale utilization of phosgene has obvious shortcomings, and scientific researchers have been working hard to find alternatives, such as phosgene polymers, carbonyl diimidazole, phenyl chloroformate, etc. However, the overall yield of the reaction is usually low and a large amount of waste is produced. At the same time, most of these compounds themselves are derived from phosgene synthesis. Taking comprehensive considerations into account, there are major limitations in using phosgene as raw material or phosgene-based substitutes to prepare asymmetric urea.
近期新的合成思路:Recent new synthesis ideas:
1、一氧化碳/二氧化碳为起始原料1. Carbon monoxide/carbon dioxide as starting raw materials
近年来,也涌现出较多新颖2-吡啶基脲合成方法。In recent years, many novel 2-pyridyl urea synthesis methods have emerged.
芳基双膦配体促进的钯催化芳基卤代物与吡啶胺反应可以得到产物脲,条件较温和,而其他必备原料,包括易爆的叠氮化钠,剧毒的一氧化碳,在反应进程中需要多关注(Adv.Synth.Catal.,2018,3602820–2824)。The palladium-catalyzed reaction of aryl halides and pyridine amines promoted by aryl bisphosphine ligands can produce urea as a product under relatively mild conditions, while other necessary raw materials, including explosive sodium azide and highly toxic carbon monoxide, will needs more attention (Adv. Synth. Catal., 2018, 3602820–2824).
以廉价易得的非金属硒为催化剂,使用一氧化碳作羰基化试剂,经过氧化羰基化反应可生成不对称取代脲,但是需要较高反应温度,一氧化碳/氧气混合气体存在潜在的爆炸危险性(Chinese Chem.Lett.,2019,30,375–378)。Using cheap and easily available non-metal selenium as the catalyst and carbon monoxide as the carbonylation reagent, an asymmetric substituted urea can be generated through an oxidative carbonylation reaction, but a higher reaction temperature is required, and the carbon monoxide/oxygen mixed gas has a potential explosion hazard (Chinese Chem. Lett., 2019, 30, 375–378).
N-(三甲基硅基)吡啶胺与二氧化碳发生热解反应,可以得到热力学有利的对称脲,然而反应条件严格、苛刻,不仅需要高温和高压,而且对设备要求极高,同时成本投入也很昂贵(Angew.Chemie Int.Ed.,2019,58,5707–5711)。The pyrolysis reaction between N-(trimethylsilyl)pyridinamine and carbon dioxide can produce thermodynamically favorable symmetric urea. However, the reaction conditions are strict and harsh, requiring not only high temperature and high pressure, but also extremely high equipment requirements and high cost investment. Very expensive (Angew. Chemie Int. Ed., 2019, 58, 5707–5711).
2、金属催化(钯,铑,铜)2. Metal catalysis (palladium, rhodium, copper)
利用氯仿替代剧毒的一氧化碳,有机磷配体辅助,极少量的表面活性剂参与下,钯催化的温和偶联反应能获取不对称的芳基取代吡啶脲,遗憾的是,仍然不能避开危险的叠氮化钠(Adv.Synth.Catal.,2018,360,4585–4593)。Using chloroform to replace highly toxic carbon monoxide, assisted by organophosphorus ligands, and with the participation of a very small amount of surfactants, asymmetric aryl-substituted pyridyl ureas can be obtained through a mild palladium-catalyzed coupling reaction. Unfortunately, the dangers cannot be avoided. of sodium azide (Adv. Synth. Catal., 2018, 360, 4585–4593).
先制备对称脲,金属铑催化下,再与另一种脲反应置换其中一侧胺片段可以获得非对称脲,但该方法需要先制备出对称脲,然后再与另一种脲反应,同样,起始原料脲的合成仍要面临传统方案中的难题,且原子经济性较差。另外,四(三苯基膦)氢化铑和有机磷配体都需要控制较苛刻的无水、无氧环境(Org.Lett.,2021,23,9382–9386)。First prepare a symmetric urea, catalyzed by metal rhodium, and then react with another urea to replace one of the amine fragments on one side to obtain an asymmetric urea. However, this method requires first preparing a symmetric urea and then reacting with another urea. Similarly, The synthesis of the starting material urea still faces difficulties in the traditional scheme, and the atom economy is poor. In addition, both tetrakis(triphenylphosphine)rhodium hydride and organophosphorus ligands need to control harsh anhydrous and oxygen-free environments (Org. Lett., 2021, 23, 9382-9386).
最近,廉价的醋酸铜催化下,经由N,O螯合铜六元环状共振态循环,结合自由基氧合策略,在敞口体系常压空气氛围中,室温下即生成吡啶脲衍生物,但是反应效率受到间位的甲基调控影响,非甲基取代的2-氨基吡啶型起始物,收率显著降低,极大限制了该方法的拓展空间(Org.Chem.Front.,2022,9,1354–1363)。Recently, under the catalysis of cheap copper acetate, through N, O chelated copper six-membered cyclic resonance state cycle, combined with the free radical oxygenation strategy, pyridine urea derivatives are generated at room temperature in an open system in a normal pressure air atmosphere. However, the reaction efficiency is affected by the control of the methyl group in the meta position. The yield of non-methyl-substituted 2-aminopyridine-type starting materials is significantly reduced, which greatly limits the expansion space of this method (Org. Chem. Front., 2022, 9, 1354–1363).
【发明内容】[Content of the invention]
针对以上现有技术的不足,本发明提供了吡啶基取代不对称脲的非金属催化、免柱层析合成方法,是一种非金属催化、免柱层析的串联反应一锅合成方法,用于合成2-吡啶基取代不对称脲,发明人探索出一个新颖的解决思路,利用氯甲酸苯酯与吡啶原位生成的配合物,发生分子内重排得到氨基甲酸苯酯盐酸盐,后续串联反应一锅合成得到目标吡啶脲(例如下面反应式的13表示的脲13,下同,其他的反应式中,例如16表示脲16),综合收率接近定量完全转化。In view of the above deficiencies in the prior art, the present invention provides a non-metal catalyzed, column chromatography-free synthesis method of pyridyl-substituted asymmetric urea, which is a non-metal catalyzed, column chromatography-free series reaction one-pot synthesis method, using For the synthesis of 2-pyridyl-substituted asymmetric urea, the inventor explored a novel solution, using the complex formed in situ between phenyl chloroformate and pyridine to undergo intramolecular rearrangement to obtain phenyl carbamate hydrochloride. The target pyridine urea (for example, urea 13 represented by 13 in the following reaction formula, the same below, in other reaction formulas, for example, 16 represents urea 16) is obtained by one-pot synthesis of the series reaction, and the comprehensive yield is close to quantitative complete conversion.
本发明的目的通过以下技术方案实现:The object of the present invention is achieved through the following technical solutions:
吡啶基取代不对称脲的非金属催化、免柱层析合成方法,包括如下步骤:The non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric ureas includes the following steps:
1)取容积5毫升(mL)带盖反应瓶,放入磁力搅拌子,将6-(4-异丙基-4H-1,2,4-三唑-3-基)吡啶-2-胺(11,IPTA)溶于乙腈后,移液枪逐滴缓慢加入氯甲酸苯酯,无氮气保护下,控制温度在30℃以下;1) Take a reaction flask with a cap of 5 ml (mL), put in a magnetic stirrer, and mix 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine After (11, IPTA) is dissolved in acetonitrile, slowly add phenyl chloroformate drop by drop with a pipette, without nitrogen protection, and control the temperature below 30°C;
所述的6-(4-异丙基-4H-1,2,4-三唑-3-基)吡啶-2-胺、乙腈、氯甲酸苯酯,按照0.1mol:300μL:15.8mg的比例;The 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine, acetonitrile, and phenyl chloroformate are in the ratio of 0.1mol:300μL:15.8mg ;
2)上述带盖反应瓶盖上密封后在室温搅拌过夜,得到澄清的盐酸盐溶液,补加等体积的四氢呋喃300μL;2) Seal the above-mentioned reaction bottle with a lid and stir at room temperature overnight to obtain a clear hydrochloride solution. Add an equal volume of 300 μL of tetrahydrofuran;
3)放大反应:依次加入N,N-二异丙基乙胺(15.5mg,20.9μL,1.2当量)、环仲胺(1.0当量),升温至50℃,反应8小时,其进度依据TLC监测,直至接近完全转化为目标产物脲;3) Amplification reaction: Add N, N-diisopropylethylamine (15.5 mg, 20.9 μL, 1.2 equivalents) and cyclic secondary amine (1.0 equivalents) in sequence, raise the temperature to 50°C, and react for 8 hours. The progress is monitored by TLC. , until it is nearly completely converted into the target product urea;
所述的N,N-二异丙基乙胺、环仲胺,按照20.9μL:0.1mol的比例;The N, N-diisopropylethylamine and cyclic secondary amine are in a ratio of 20.9 μL: 0.1 mol;
4)上步骤所述的放大反应反应完毕后,采用乙酸乙酯或者氯仿来溶解反应混合物,然后用旋转蒸发仪除去溶剂,再分别用水、氢氧化钠水溶液各洗涤2次,用无水硫酸钠干燥有机相,用旋转蒸发仪除去溶剂,即得吡啶基取代不对称脲,直接送核磁检验分析。4) After the amplification reaction described in the above step is completed, use ethyl acetate or chloroform to dissolve the reaction mixture, then use a rotary evaporator to remove the solvent, and then wash twice with water, sodium hydroxide aqueous solution, and anhydrous sodium sulfate. Dry the organic phase and remove the solvent with a rotary evaporator to obtain the pyridyl-substituted asymmetric urea, which can be sent directly to NMR analysis.
本发明中:In the present invention:
步骤2)所述的补加等体积的四氢呋喃,是混合反应液中需要补加的第二部分溶剂,根据不同反应底物的极性,同样可用等体积的乙腈或者二氯乙烷代替四氢呋喃,收率基本不受影响。The addition of an equal volume of tetrahydrofuran as described in step 2) is the second part of the solvent that needs to be added to the mixed reaction solution. According to the polarity of different reaction substrates, an equal volume of acetonitrile or dichloroethane can also be used instead of tetrahydrofuran. The yield is basically not affected.
步骤3)所述的环仲胺,可以用芳香胺或脂环胺替换,具体包括1,2,3,4-四氢喹啉、具有伯胺(-NH2)和仲胺(-NH-)结构的脂肪胺、脂环胺、醇胺、芳香胺、芳杂环胺;6-(4-异丙基-4H-1,2,4-三唑-3-基)吡啶-2-胺(IPTA)也可以用间位、对位取代的吡啶类型衍生物替换。The cyclic secondary amine described in step 3) can be replaced with an aromatic amine or an alicyclic amine, specifically including 1,2,3,4-tetrahydroquinoline, primary amine (-NH 2 ) and secondary amine (-NH- ) structure of aliphatic amines, alicyclic amines, alcohol amines, aromatic amines, aromatic heterocyclic amines; 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (IPTA) can also be replaced with meta- or para-substituted pyridine-type derivatives.
基于以上反应机理,具体的,对步骤3)反应的底物进行替换,以结构多样性的一系列芳香胺或脂环胺代替上述环仲胺作为起始原料,收率都接近等量转化,包含sp2C、sp3C、O、S、N原子的环仲胺,主要包括以下结构(脲16-脲27):Based on the above reaction mechanism, specifically, the substrate of the reaction in step 3) is replaced, and a series of aromatic amines or alicyclic amines with structural diversity are used as starting materials instead of the above-mentioned cyclic secondary amines, and the yields are close to equivalent conversions. Cyclic secondary amines containing sp 2 C, sp 3 C, O, S, and N atoms mainly include the following structures (urea 16-urea 27):
与此类似,该反应历程进一步替换适用于间位、对位取代的吡啶类型衍生物,相应的分子间重排串联反应为主,进而介导吡啶脲的构建。Similarly, the reaction process is further adapted to meta- and para-substituted pyridine-type derivatives, and the corresponding intermolecular rearrangement series reactions are the main ones, thereby mediating the construction of pyridine urea.
同样,鉴于上述反应对一系列脂环胺、芳香胺(如位阻较大、活性较低的1,2,3,4-四氢喹啉)适用性都良好,多数转化率都接近95%,进一步的,具有伯胺(-NH2)和仲胺(-NH-)结构的脂肪胺、脂环胺、醇胺、芳香胺、芳杂环胺同样可应用此方案得到相应吡啶基取代脲。Similarly, given that the above reaction has good applicability to a series of alicyclic amines and aromatic amines (such as 1,2,3,4-tetrahydroquinoline with greater steric hindrance and lower activity), most conversion rates are close to 95% , further, aliphatic amines, alicyclic amines, alcohol amines, aromatic amines, and aromatic heterocyclic amines with primary amine (-NH 2 ) and secondary amine (-NH-) structures can also be used to obtain the corresponding pyridyl-substituted ureas. .
上述吡啶基取代不对称脲的非金属催化、免柱层析合成方法,提供了一个简单高效、可持续的绿色合成方案,以极少量废弃物和极高原子经济性构建不对称脲。The above-mentioned non-metal-catalyzed, column-chromatography-free synthesis method of pyridyl-substituted asymmetric ureas provides a simple, efficient, and sustainable green synthesis scheme to construct asymmetric ureas with very little waste and extremely high atom economy.
针对上述吡啶基取代不对称脲的非金属催化、免柱层析合成方法,发明人提出一个合理的机制来评估反应效果,在三乙胺存在情况下,由于三乙胺氮原子比吡啶环上以及环外芳香氮原子亲核性强,氯甲酸苯酯可能先与三乙胺氮原子发生反应,产生活性的铵离子中间体,此中间体再和吡啶胺(IPTA)发生热力学途径(路径I)占主导地位的双分子反应。Regarding the above-mentioned non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric urea, the inventor proposed a reasonable mechanism to evaluate the reaction effect. In the presence of triethylamine, since the nitrogen atom of triethylamine is larger than the nitrogen atom on the pyridine ring, As the exocyclic aromatic nitrogen atom is highly nucleophilic, phenyl chloroformate may first react with the triethylamine nitrogen atom to produce an active ammonium ion intermediate, which then reacts with pyridylamine (IPTA) in a thermodynamic pathway (Path I ) dominates the bimolecular reaction.
在缺少三乙胺时,推测反应由氯甲酸苯酯与吡啶氮原子原位生成的配合物引发,属于动力学途径(路径II)占主导,再通过分子内重排得到氨基甲酸苯酯盐酸盐;而路径II能量势垒较低,为优势途径。密度泛函理论(Density Functional Theory,DFT)研究,DFT证实了此推论的合理性:In the absence of triethylamine, it is speculated that the reaction is initiated by a complex formed in situ between phenyl chloroformate and pyridine nitrogen atoms. The kinetic pathway (path II) dominates, and then phenyl carbamate hydrochloride is obtained through intramolecular rearrangement. salt; while path II has a lower energy barrier and is the dominant path. Density Functional Theory (DFT) research, DFT confirmed the rationality of this inference:
DFT计算验证生成化合物2的反应路径:DFT calculations verify the reaction path to generate compound 2:
关键的串联反应一锅合成得到目标产物吡啶脲,为系统研究其氨解机理,通过密度泛函理论模型,包括引入叔丁氧羰基(Boc)、苄氧羰基(Cbz)、苯氧羰基(PhCO)等不同活化方式的3种中间体,分别比较其BAC2(路径Ⅲ,加成-消除分步途径,通过两性离子态中间体)、E1cB路径(路径Ⅳ,通过中性异氰酸酯中间体的消除-加成机制)和协同(concerted)机理(路径Ⅴ,协同反应经过一步完成,新键生成和旧键断裂是同时发生的)。The key series reaction is one-pot synthesis to obtain the target product pyridine urea. In order to systematically study its aminolysis mechanism, density functional theory model is used, including the introduction of tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), phenoxycarbonyl (PhCO) ) and other three intermediates with different activation modes, respectively compare their BAC2 (Path Ⅲ, addition-elimination step-by-step pathway, through the zwitterionic intermediate), E1cB path (Path Ⅳ, through the elimination of neutral isocyanate intermediate- Addition mechanism) and concerted mechanism (Path V, the concerted reaction is completed in one step, and the formation of new bonds and the breaking of old bonds occur at the same time).
路径III(BAC2,加成消去路径):Path III (BAC2, addition elimination path):
路径IV(异氰酸脂,消去加成路径):Path IV (isocyanate, elimination of addition path):
路径V(协调机理):Path V (coordination mechanism):
通过计算反应发生的能垒(氨解的反应能垒,kcal/mol):By calculating the energy barrier for the reaction to occur (reaction energy barrier for ammonolysis, kcal/mol):
对于路径Ⅲ,第一步的加成反应是决速步骤,对于t-Bu,Bn和Ph取代基时的能垒分别为42.7,38.1和33.3kcal/mol;路径IV中决速步骤的反应能垒分别为48.1,51.2和51.5kcal/mol;路径V的反应能垒分别为42.4,30.1和14.9kcal/mol。反应能垒表明路径V是最可能的途径,尽管协同反应机理不常见。For Path III, the first step of the addition reaction is the rate-determining step, and the energy barriers for t-Bu, Bn and Ph substituents are 42.7, 38.1 and 33.3 kcal/mol respectively; the reaction energy of the rate-determining step in Path IV The barriers are 48.1, 51.2 and 51.5kcal/mol respectively; the reaction energy barriers of path V are 42.4, 30.1 and 14.9kcal/mol respectively. The reaction energy barriers indicate that path V is the most likely pathway, although cooperative reaction mechanisms are uncommon.
亲核试剂吗啡啉分子中的氮原子进攻亲电试剂羰基中的碳原子,为四元环过渡态,在C-N键部分生成和酰氧键部分断裂的同时NH上的一个氢原子转移到酰氧键的氧原子上,保持了过渡态的电中性。一般情况下,BAC2或者E1cB途径为经典理论中的优势通路,上述计算结论与此并不一致,但是更符合实际反应中观察到的现象及结果(高温85℃,中间体不降解,且反应速度明显加快,2.5小时,转化率95.8%)。The nitrogen atom in the morpholine molecule of the nucleophile attacks the carbon atom in the carbonyl group of the electrophile, which is a four-membered ring transition state. While the C-N bond is partially generated and the acyloxy bond is partially broken, a hydrogen atom on the NH is transferred to the acyloxy On the oxygen atom of the bond, the electrical neutrality of the transition state is maintained. In general, the BAC2 or E1cB pathway is the dominant pathway in classical theory. The above calculation conclusion is not consistent with this, but is more consistent with the phenomena and results observed in actual reactions (high temperature 85°C, intermediates are not degraded, and the reaction speed is obvious Speed up, 2.5 hours, conversion rate 95.8%).
为探索其详细的底物作用机制,密切结合并对比分析实验数据,发明人运用理论与计算化学方法,经过详细的密度泛函理论(Density Functional Theory,DFT)研究,得出结论:In order to explore its detailed substrate action mechanism, closely combine and comparatively analyze the experimental data, the inventor used theoretical and computational chemistry methods, and after detailed density functional theory (DFT) research, came to the conclusion:
1、本发明所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法,反应由氯甲酸苯酯与吡啶原位生成的配合物引发,通过分子内重排得到氨基甲酸苯酯盐酸盐,后续串联反应一锅合成得到目标产物吡啶脲;1. The non-metal catalyzed and column chromatography-free synthesis method of pyridyl-substituted asymmetric urea according to the present invention. The reaction is initiated by the complex generated in situ between phenyl chloroformate and pyridine, and phenyl carbamate is obtained through intramolecular rearrangement. ester hydrochloride, followed by a one-pot synthesis of series reactions to obtain the target product pyridinourea;
2、同时,发明人发现现有技术中提出的涉及一个分步进行得到两性离子中间态的过程(加成-消除;路径III),或者中性异氰酸酯的经典中间态(消除-加成;路径IV),二者整体能垒过高,均难以实现;而本发明所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法,依据一个新键生成和旧键断裂同时发生的协同(concerted)机理(路径V),具备更有利的整体能量势垒,理论计算能提供有说服力的数据,能合理解释温和有机碱催化所关联的调控因素;本发明所述的反应历程能进一步拓展适用于间位、对位取代的吡啶类型衍生物,相应的分子间重排串联反应为主,进而介导吡啶脲的构建。2. At the same time, the inventor found that the process proposed in the prior art involves a step-by-step process to obtain an intermediate state of a zwitterion (addition-elimination; Path III), or the classic intermediate state of neutral isocyanate (elimination-addition; Path III) IV), the overall energy barrier of both is too high, making it difficult to realize; and the non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric urea according to the present invention is based on the simultaneous generation of a new bond and the breaking of the old bond. The concerted mechanism (path V) has a more favorable overall energy barrier, and theoretical calculations can provide convincing data and can reasonably explain the regulatory factors associated with mild organic base catalysis; the reaction process described in the present invention It can be further expanded to be suitable for meta- and para-substituted pyridine-type derivatives, and the corresponding intermolecular rearrangement series reactions are the main ones, thereby mediating the construction of pyridine urea.
和现有技术相比,本发明具有如下优点:Compared with the prior art, the present invention has the following advantages:
1、本发明所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法,是一种新颖的串联反应一锅方法,针对一系列芳香胺和脂肪胺,收率都接近等量转化,包含sp2C、sp3C、O、S、N原子的环仲胺上给电子与吸电子基团都不影响反应效率。1. The non-metal catalyzed and column-chromatography-free synthesis method of pyridyl-substituted asymmetric urea according to the present invention is a novel one-pot series reaction method. For a series of aromatic amines and aliphatic amines, the yields are close to those of Quantity conversion, electron-donating and electron-withdrawing groups on cyclic secondary amines containing sp 2 C, sp 3 C, O, S, and N atoms do not affect the reaction efficiency.
2、本发明所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法,有多种组合溶剂,能适应不同极性的起始原料,应用范围广;催化条件接近中性,相对低温下几乎完全转化为目标脲,能有效抑制或者消除不良副反应产物(如手性中心的消旋化)。2. The non-metal catalytic and column chromatography-free synthesis method of pyridyl-substituted asymmetric urea according to the present invention has a variety of solvent combinations, can adapt to starting materials of different polarities, and has a wide range of applications; the catalytic conditions are close to neutral , almost completely converted into the target urea at relatively low temperature, which can effectively suppress or eliminate undesirable side reaction products (such as racemization of chiral centers).
3、本发明所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法,对不同张力的环系和环上取代的手性基团兼容性都良好,且工艺流程易于放大,因此特别适用于价格昂贵的手性药物或相应高附加值关键中间体的制备,极其便于大规模工业化应用。3. The non-metal-catalyzed, column-chromatography-free synthesis method of pyridyl-substituted asymmetric urea according to the present invention has good compatibility with ring systems of different tensions and chiral groups substituted on the ring, and the process flow is easy to scale up. , so it is particularly suitable for the preparation of expensive chiral drugs or corresponding high value-added key intermediates, and is extremely convenient for large-scale industrial application.
【附图说明】[Picture description]
图1是本发明所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法的反应条件优化的图;Figure 1 is a diagram illustrating the optimization of the reaction conditions of the non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric urea according to the present invention;
图2是本发明所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法的串联反应一锅合成原理(协同路径)及步骤3)反应的底物进行替换(邻、间、对位取代型吡啶脲)的图。Figure 2 shows the one-pot synthesis principle (cooperative path) of the series reaction of the non-metal catalyzed, column chromatography-free synthesis method of pyridyl-substituted asymmetric urea according to the present invention and the substrate substitution (ortho, meta) reaction in step 3). , para-substituted pyridyl urea).
【具体实施方式】【Detailed ways】
以下结合实施例对本发明的具体实施方式做进一步说明。The specific embodiments of the present invention will be further described below in conjunction with examples.
实施例1:Example 1:
吡啶基取代不对称脲的非金属催化、免柱层析合成方法,包括如下步骤:The non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric ureas includes the following steps:
1)取容积5毫升带盖反应瓶,放入磁力搅拌子,6-(4-异丙基-4H-1,2,4-三唑-3-基)吡啶-2-胺(IPTA,20.3mg,0.1mol,1.0当量)溶于乙腈(300μL,15倍体积)后,移液枪逐滴缓慢加入氯甲酸苯酯(15.8mg,12.6μL,1.0当量),一般无需氮气保护,控制温度在30℃以下;1) Take a reaction bottle with a cap of 5 ml, put in a magnetic stirrer, 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (IPTA, 20.3 mg, 0.1 mol, 1.0 equivalent) dissolved in acetonitrile (300 μL, 15 times the volume), slowly add phenyl chloroformate (15.8 mg, 12.6 μL, 1.0 equivalent) drop by drop with a pipette. Nitrogen protection is generally not required, and the temperature is controlled at Below 30℃;
2)盖上密封后在室温搅拌过夜,得到澄清的盐酸盐溶液,补加等体积的四氢呋喃(300μL);2) Cover and seal, stir at room temperature overnight to obtain a clear hydrochloride solution, add an equal volume of tetrahydrofuran (300 μL);
3)然后,依次加入N,N-二异丙基乙胺(15.5mg,20.9μL,1.2当量)、环仲胺吗啡啉(1.0当量),升温至50℃,反应8小时,其进度依据TLC监测,通常,8小时足够接近完全转化为目标产物脲;3) Then, add N,N-diisopropylethylamine (15.5 mg, 20.9 μL, 1.2 equivalent) and cyclic secondary amine morpholine (1.0 equivalent) in sequence, raise the temperature to 50°C, and react for 8 hours. The progress is based on TLC Monitoring, usually, 8 hours is close enough to complete conversion to the target product urea;
4)放大反应(0.1mmol规模)完毕后,用常规溶剂乙酸乙酯或者氯仿都可以用来溶解反应混合物,然后用旋转蒸发仪除去溶剂,再分别用适量水、氢氧化钠水溶液各洗涤2次,无水硫酸钠干燥有机相,旋转蒸发仪除去溶剂,即得粗品脲,直接送核磁检验分析,结果显示纯度高,起始原料接近定量完全转化。4) After the amplification reaction (0.1 mmol scale) is completed, the conventional solvent ethyl acetate or chloroform can be used to dissolve the reaction mixture, then use a rotary evaporator to remove the solvent, and then wash twice with an appropriate amount of water and sodium hydroxide aqueous solution. , dry the organic phase with anhydrous sodium sulfate, remove the solvent with a rotary evaporator, and obtain the crude urea, which is directly sent for nuclear magnetic examination and analysis. The results show that the purity is high, and the starting raw materials are almost completely converted quantitatively.
目标产物脲13收率97.6%。The yield of the target product urea 13 was 97.6%.
实施例2:Example 2:
吡啶基取代不对称脲的非金属催化、免柱层析合成方法,包括如下步骤:The non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric ureas includes the following steps:
1)取容积5毫升带盖反应瓶,放入磁力搅拌子,6-(4-异丙基-4H-1,2,4-三唑-3-基)吡啶-2-胺(IPTA,20.3mg,0.1mol,1.0当量)溶于乙腈(300μL,15倍体积)后,移液枪逐滴缓慢加入氯甲酸苯酯(15.8mg,12.6μL,1.0当量),一般无需氮气保护,控制温度在30℃以下;1) Take a reaction bottle with a cap of 5 ml, put in a magnetic stirrer, 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (IPTA, 20.3 mg, 0.1 mol, 1.0 equivalent) dissolved in acetonitrile (300 μL, 15 times the volume), slowly add phenyl chloroformate (15.8 mg, 12.6 μL, 1.0 equivalent) drop by drop with a pipette. Nitrogen protection is generally not required, and the temperature is controlled at Below 30℃;
2)盖上密封后在室温搅拌过夜,得到澄清的盐酸盐溶液,补加等体积的乙腈(300μL);2) Cover and seal, stir at room temperature overnight to obtain a clear hydrochloride solution, add an equal volume of acetonitrile (300 μL);
3)然后,依次加入N,N-二异丙基乙胺(15.5mg,20.9μL,1.2当量)、环仲胺吗啡啉(1.0当量),升温至50℃,反应8小时,其进度依据TLC监测,通常,8小时足够接近完全转化为目标产物脲;3) Then, add N,N-diisopropylethylamine (15.5 mg, 20.9 μL, 1.2 equivalent) and cyclic secondary amine morpholine (1.0 equivalent) in sequence, raise the temperature to 50°C, and react for 8 hours. The progress is based on TLC Monitoring, usually, 8 hours is close enough to complete conversion to the target product urea;
4)放大反应(0.1mmol规模)完毕后,用常规溶剂乙酸乙酯或者氯仿都可以用来溶解反应混合物,然后用旋转蒸发仪除去溶剂,再分别用适量水、氢氧化钠水溶液各洗涤2次,无水硫酸钠干燥有机相,旋转蒸发仪除去溶剂,即得粗品脲,直接送核磁检验分析,结果显示纯度高,起始原料接近定量完全转化。4) After the amplification reaction (0.1 mmol scale) is completed, the conventional solvent ethyl acetate or chloroform can be used to dissolve the reaction mixture, then use a rotary evaporator to remove the solvent, and then wash twice with an appropriate amount of water and sodium hydroxide aqueous solution. , dry the organic phase with anhydrous sodium sulfate, remove the solvent with a rotary evaporator, and obtain the crude urea, which is directly sent for nuclear magnetic examination and analysis. The results show that the purity is high, and the starting raw materials are almost completely converted quantitatively.
目标产物脲13收率89.8%。The yield of the target product urea 13 was 89.8%.
实施例3:Example 3:
吡啶基取代不对称脲的非金属催化、免柱层析合成方法,包括如下步骤:The non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric ureas includes the following steps:
1)取容积5毫升带盖反应瓶,放入磁力搅拌子,6-(4-异丙基-4H-1,2,4-三唑-3-基)吡啶-2-胺(IPTA,20.3mg,0.1mol,1.0当量)溶于乙腈(300μL,15倍体积)后,移液枪逐滴缓慢加入氯甲酸苯酯(15.8mg,12.6μL,1.0当量),一般无需氮气保护,控制温度在30℃以下;1) Take a reaction bottle with a cap of 5 ml, put in a magnetic stirrer, 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (IPTA, 20.3 mg, 0.1 mol, 1.0 equivalent) dissolved in acetonitrile (300 μL, 15 times the volume), slowly add phenyl chloroformate (15.8 mg, 12.6 μL, 1.0 equivalent) drop by drop with a pipette. Nitrogen protection is generally not required, and the temperature is controlled at Below 30℃;
2)盖上密封后在室温搅拌过夜,得到澄清的盐酸盐溶液,补加等体积的二氯乙烷(300μL);2) Cover and seal, stir at room temperature overnight to obtain a clear hydrochloride solution, add an equal volume of dichloroethane (300 μL);
3)然后,依次加入N,N-二异丙基乙胺(15.5mg,20.9μL,1.2当量)、环仲胺吗啡啉(1.0当量),升温至50℃,反应8小时,其进度依据TLC监测,通常,8小时足够接近完全转化为目标产物脲;3) Then, add N,N-diisopropylethylamine (15.5 mg, 20.9 μL, 1.2 equivalent) and cyclic secondary amine morpholine (1.0 equivalent) in sequence, raise the temperature to 50°C, and react for 8 hours. The progress is based on TLC Monitoring, usually, 8 hours is close enough to complete conversion to the target product urea;
4)放大反应(0.1mmol规模)完毕后,用常规溶剂乙酸乙酯或者氯仿都可以用来溶解反应混合物,然后用旋转蒸发仪除去溶剂,再分别用适量水、氢氧化钠水溶液各洗涤2次,无水硫酸钠干燥有机相,旋转蒸发仪除去溶剂,即得粗品脲,直接送核磁检验分析,结果显示纯度高,起始原料接近定量完全转化。4) After the amplification reaction (0.1 mmol scale) is completed, the conventional solvent ethyl acetate or chloroform can be used to dissolve the reaction mixture, then use a rotary evaporator to remove the solvent, and then wash twice with an appropriate amount of water and sodium hydroxide aqueous solution. , dry the organic phase with anhydrous sodium sulfate, remove the solvent with a rotary evaporator, and obtain the crude urea, which is directly sent for nuclear magnetic examination and analysis. The results show that the purity is high, and the starting raw materials are almost completely converted quantitatively.
目标产物脲13收率91.7%。The yield of the target product urea 13 was 91.7%.
实施例4-实施例15Example 4-Example 15
图2是本申请所述的吡啶基取代不对称脲的非金属催化、免柱层析合成方法的串联反应一锅合成原理(协同路径)及步骤3)反应的底物进行替换(邻、间、对位取代型吡啶脲)的图。Figure 2 shows the one-pot synthesis principle (cooperative path) of the series reaction of the non-metal catalyzed, column-free chromatography synthesis method of pyridyl-substituted asymmetric ureas described in the present application and the substrate substitution (ortho-, meta-) reaction in step 3). , para-substituted pyridyl urea).
参照实施例1,将步骤3)中的环仲胺吗啡啉用其他成分替代后,以高收率得到的相应产物脲分别为:Referring to Example 1, after replacing the cyclic secondary amine morpholine in step 3) with other components, the corresponding products urea obtained in high yield are:
采用本申请的吡啶基取代不对称脲的非金属催化、免柱层析合成方法,实施例1-15得到的吡啶基取代不对称脲的收率为89.8-97.6%。Using the non-metal-catalyzed, column-chromatography-free synthesis method of pyridyl-substituted asymmetric urea of the present application, the yield of the pyridyl-substituted asymmetric urea obtained in Examples 1-15 is 89.8-97.6%.
对比例:Comparative ratio:
国内外绿色合成设计:Green synthetic design at home and abroad:
对比例1:Comparative example 1:
无溶剂、无卤素原子的经济实用型2-吡啶基取代脲合成方案,以容易制备或商业化的吡啶N-氧化物和二烷基氰酰胺为起始原料,在甲烷磺酸催化下进行,具有较广泛的底物适用性,对吡啶环上的给电子和吸电子取代基都不敏感,且产率较优(63-92%;19例)(GreenChem.,2016,18,6630–6636)。An economical and practical synthesis scheme of 2-pyridyl-substituted urea without solvent and halogen atoms, using pyridine N-oxide and dialkyl cyanamide as starting materials, which are easy to prepare or commercialize, and carried out under the catalysis of methanesulfonic acid. It has wider substrate applicability, is not sensitive to electron-donating or electron-withdrawing substituents on the pyridine ring, and has excellent yield (63-92%; 19 cases) (GreenChem., 2016, 18, 6630-6636 ).
对比例2:Comparative example 2:
吡啶基/喹啉基部分取代不对称脲的合成方法被开发出来,借助N,N-二甲基-N’-杂芳基脲的重新胺化(转胺)反应,该方案无需金属、碱催化剂,适用于多种芳基和烷基胺(分离产率40-96%;50多例);有机胺的反应活性不受其自身供体或受体以及不同官能团化基团的影响,易于放大到克级别。根据实验数据,结合理论计算推导此反应通过异氰酸酯中间体进行(Adv.Synth.Catal.,2022,364,1295–1304)。A synthetic method for pyridyl/quinolyl partially substituted asymmetric ureas was developed. With the help of the re-amination (transamination) reaction of N, N-dimethyl-N'-heteroaryl urea, this scheme does not require metals or bases. Catalyst, suitable for a variety of aryl and alkyl amines (isolated yield 40-96%; more than 50 cases); the reactivity of organic amines is not affected by their own donors or acceptors and different functionalized groups, and is easy to Zoom in to the gram level. Based on experimental data and theoretical calculations, it is deduced that this reaction proceeds through an isocyanate intermediate (Adv. Synth. Catal., 2022, 364, 1295–1304).
对比例3:Comparative example 3:
一种水相制备多种2-喹啉基取代脲的绿色环保方法,在温和无毒,非碱性和有机溶剂条件下进行。其放大实验中,产品可以通过简单的过滤和乙醇洗涤快速收集,使用易得的原材料,100%的原子经济性、高产率和优异的区域选择性增强了该方案的实用性(ACSSustain.Chem.Eng.,2019,7,7193–7199)。A green and environmentally friendly method for preparing various 2-quinolyl-substituted ureas in aqueous phase under mild, non-toxic, non-alkaline and organic solvent conditions. In its scale-up experiment, the product can be quickly collected by simple filtration and ethanol washing, using readily available raw materials, 100% atom economy, high yield and excellent regioselectivity enhance the practicality of this scheme (ACSSustain.Chem. Eng., 2019, 7, 7193–7199).
上述对比例1-3三个相似关联设计的突出局限在于,都是基于吡啶N-氧化衍生物为起始原料,其制备过程需要较复杂的酶体系,或者大量的酸性过氧化氢,且收率中等,因此不利于放大。The prominent limitation of the three similar correlation designs of Comparative Examples 1-3 above is that they are all based on pyridine N-oxidation derivatives as starting materials, and their preparation process requires a more complex enzyme system or a large amount of acidic hydrogen peroxide, and the collection The rate is medium, so it is not conducive to amplification.
同时,二烷基氰酰胺和碳二亚胺型底物的制备,都会产生较多的废弃物,且反应条件也较苛刻,不易利用常规实验设备大量制取。此外,硫酸铜五水合物催化下,只得到痕量的2-异喹啉基或者吡啶基取代脲,推测可能是这两种类型对应的N-氧化物活性都较低。At the same time, the preparation of dialkyl cyanamide and carbodiimide-type substrates will produce a lot of waste, and the reaction conditions are also harsh, making it difficult to prepare large quantities using conventional experimental equipment. In addition, under the catalysis of copper sulfate pentahydrate, only trace amounts of 2-isoquinolyl or pyridyl-substituted urea were obtained. It is speculated that the N-oxides corresponding to these two types have low activity.
对比例4:Comparative example 4:
最近研究表明,利用2-氨基吡啶盐与芳胺的串联反应,可以得到2-吡啶基脲衍生物,此策略可耐受广泛的官能团,产率适中至良好。推测该反应为级联环化反应,经由分子间亲核加成、开环和去甲基化历程。但是,邻位吡啶盐及芳香胺的特有组合,限制了其拓展范围(Tetrahedron Lett.,2019,60,150939)。Recent studies have shown that 2-pyridyl urea derivatives can be obtained by utilizing the tandem reaction of 2-aminopyridinium salts with aromatic amines. This strategy can tolerate a wide range of functional groups and has moderate to good yields. It is speculated that this reaction is a cascade cyclization reaction through intermolecular nucleophilic addition, ring opening and demethylation. However, the unique combination of ortho-pyridinium salts and aromatic amines limits its expansion scope (Tetrahedron Lett., 2019, 60, 150939).
以上所述仅为本发明的优选实施方式,应当指出,对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,做出若干改进和变化,这些都属于本发明的保护范围。The above are only preferred embodiments of the present invention. It should be pointed out that for those of ordinary skill in the art, several improvements and changes can be made without departing from the creative concept of the present invention, and these all belong to the protection of the present invention. scope.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310325909.3A CN116444485B (en) | 2023-03-30 | 2023-03-30 | Nonmetallic catalysis and column-free chromatographic synthesis method for pyridyl substituted asymmetric urea |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310325909.3A CN116444485B (en) | 2023-03-30 | 2023-03-30 | Nonmetallic catalysis and column-free chromatographic synthesis method for pyridyl substituted asymmetric urea |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116444485A CN116444485A (en) | 2023-07-18 |
CN116444485B true CN116444485B (en) | 2024-01-23 |
Family
ID=87126702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310325909.3A Active CN116444485B (en) | 2023-03-30 | 2023-03-30 | Nonmetallic catalysis and column-free chromatographic synthesis method for pyridyl substituted asymmetric urea |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116444485B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105008360A (en) * | 2012-12-20 | 2015-10-28 | Ucb生物制药私人有限公司 | Therapeutically active pyrazolo-pyrimidine derivatives |
CN107207515A (en) * | 2015-01-16 | 2017-09-26 | 豪夫迈·罗氏有限公司 | Pyrazine compound for treating infectious diseases |
CN108289893A (en) * | 2015-10-01 | 2018-07-17 | 拜奥克里斯特制药公司 | Human plasma kallikrein inhibitor |
CN108948004A (en) * | 2016-05-27 | 2018-12-07 | 杭州英创医药科技有限公司 | Heterocyclic compound as FGFR4 inhibitor |
CN110240598A (en) * | 2018-03-09 | 2019-09-17 | 上海翰森生物医药科技有限公司 | The Preparation Method And Their Intermediate compound of carboxamides derivatives |
CN113248497A (en) * | 2018-07-27 | 2021-08-13 | 北京加科思新药研发有限公司 | Fused ring derivatives useful as FGFR4 inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017160861A1 (en) * | 2016-03-15 | 2017-09-21 | The Regents Of The University Of California | Inhibitors for soluble epoxide hydrolase (seh) and fatty acid amide hydrolase (faah) |
-
2023
- 2023-03-30 CN CN202310325909.3A patent/CN116444485B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105008360A (en) * | 2012-12-20 | 2015-10-28 | Ucb生物制药私人有限公司 | Therapeutically active pyrazolo-pyrimidine derivatives |
CN107207515A (en) * | 2015-01-16 | 2017-09-26 | 豪夫迈·罗氏有限公司 | Pyrazine compound for treating infectious diseases |
CN108289893A (en) * | 2015-10-01 | 2018-07-17 | 拜奥克里斯特制药公司 | Human plasma kallikrein inhibitor |
CN108948004A (en) * | 2016-05-27 | 2018-12-07 | 杭州英创医药科技有限公司 | Heterocyclic compound as FGFR4 inhibitor |
CN110240598A (en) * | 2018-03-09 | 2019-09-17 | 上海翰森生物医药科技有限公司 | The Preparation Method And Their Intermediate compound of carboxamides derivatives |
CN113248497A (en) * | 2018-07-27 | 2021-08-13 | 北京加科思新药研发有限公司 | Fused ring derivatives useful as FGFR4 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CN116444485A (en) | 2023-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008241602B2 (en) | A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile 701 | |
CN110903248B (en) | Synthesis method of 5-chloro-4-aminopyridazine | |
CN118164971A (en) | Method for preparing carbostyril | |
WO2023284058A1 (en) | Method for preparing chiral synthetic nicotine | |
CN102659662A (en) | A synthetic method of 3-R-3-hydroxy-2-oxindole compound | |
WO2023004918A1 (en) | Preparation method for synthesizing chiral nicotine from chiral tert-butyl sulfinamide | |
JP2001514252A (en) | Branched alkoxy substituted 2-aminopyridines as NOS inhibitors | |
CN114957247A (en) | Synthesis method of Rimegepant and intermediate thereof | |
CN105732619A (en) | Synthesizing method of 5,6,7,8-tetrahydropyridino-[2,3-d]pyrimidine compound | |
CN116444485B (en) | Nonmetallic catalysis and column-free chromatographic synthesis method for pyridyl substituted asymmetric urea | |
CN109180682B (en) | A kind of chiral nitrogen heterocyclic carbene precursor compound with bicyclic skeleton and preparation method thereof | |
CN103111323B (en) | Chirality N, N-dialkyl-1, 2-diaminocyclohexane catalyst as well as preparation method and application thereof | |
CN101759601A (en) | Method for preparing chiral alpha-unnatural amino acid by transition metal complex | |
CN110256441A (en) | A kind of Ba Ruike replaces the preparation method of Buddhist nun | |
HRP20020762A2 (en) | N-(heterocyklyl)benzene or pyridine sulphonamides as antithrombotic agens and anticoagulants | |
CN110684028B (en) | Preparation method of 2, 6-diazabicyclo [3,3,0] octane compound | |
WO2022048025A1 (en) | Method for synthesizing atorvastatin calcium intermediate by using multi-component one-pot method | |
JP2023548368A (en) | Method for producing heterocyclic methanone compound and its azabicyclo intermediate | |
CN108586486B (en) | A kind of preparation method of aryl-substituted thienopyrimidine compounds | |
CN111233827A (en) | A kind of 2,5-disubstituted selenophene compound and its synthesis method | |
CN118420541A (en) | Preparation method of enzae Lu An | |
CN115093397B (en) | A compound, synthesis method and application for treating tumor | |
CN115215783B (en) | Propargyl substituted chiral 3-amino-3, 3-disubstituted oxindole compound, and synthetic method and application thereof | |
CN112500445B (en) | Preparation method of β-nicotinamide riboside | |
CN119371401B (en) | 4-(1H-pyrazol-4-yl)pyridine derivatives targeting lipoprotein transport pathway of Gram-negative bacteria, compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |